1999 Lumenis Lightsheer EP For Sale http://www.rockbottomlasers.com 1999 Lumenis Lightsheer EP with Optipulse Upgrade for Skin Type 4-6 and 400 ms Treatment Range; Manufactured 07/1999; Excellent Operating and Cosmetic Condition, One Owner, Retiring; Pulse Count = 192767; Auto Head Room = 1.45; Includes: Diode Handpiece, Key, Footswitch, Operators Manual, (2) Operator Eyewear, and 90 Day Warranty; Crating, Shipping, and Insurance Included in Lower 48 States on All our Inventory http://www.rockbottomlasers.com 800-794-1097 By: Rock Bottom Lasers … Continue reading →

American Academy of Neurology hosts the largest North American gathering of MS researchers San Diego, CA (PRWEB) March 12, 2013 The AAN meeting will be held March 16-23 and is the largest gathering of neurologists in North America. The AAN meeting gives us a preview of the latest MS research, says Anne St-Michel, publisher of MSology. Its an important event and were going to provide the most extensive on-site news coverage. We need to provide up-to-date information to the hundreds of people who access MSology every day. MSology debuted last year as a free information site offering the latest research news on MS, tips on living with the disease, and practical advice to help in making decisions. The website also provides in-depth articles, such as the recent piece addressing whether injectable therapies will continue to be used as more oral and infusion drugs become available to treat MS. New MS research will be presented on four key days, and MSology will be on hand in San Diego, CA, to provide daily coverage. MSology Editor Steven Manners will also Tweet throughout the conference on MSologys Twitter account (@MSology). We need to bring home the important information about new MS research to … Continue reading →

MS Awareness Week March 11 - 17, 2013 Every Connection Counts at MSconnection.org NEW YORK, March 11, 2013 /PRNewswire-USNewswire/ -- Multiple sclerosis is a life altering disease that affects each person in a unique and different way. MS destroys connections, divides minds from bodies, pulls people from their lives and away from one another. Millions of people are affected by MS worldwide. There is no cure. Therefore, it's only fitting that connections would be its greatest enemy. As more connections are formed, more knowledge is shared, more questions are asked, more resources are gathered, and more hope is provided to help people living with MS move their lives forward. Every connection counts. (Logo: http://photos.prnewswire.com/prnh/20090302/DC77093LOGO) Connect during MS Awareness Week March 11-17People impacted by MS are connecting across the nation during Multiple Sclerosis Awareness Week March 11 17 to combine their efforts, knowledge and hope in order to move us closer to a world free of multiple sclerosis. The National MS Society is a prominent force in forging connections among people with MS, their friends and family who raise awareness and funds; health professionals who treat those with MS; and, researchers who work to stop the disease, restore the function it … Continue reading →

Public release date: 11-Mar-2013 [ | E-mail | Share ] Contact: Dawn Peters sciencenewsroom@wiley.com 781-388-8408 Wiley A recent clinical trial found that interferon-1a (INF) and glatiramer acetate (GA), two of the most commonly prescribed drugs for multiple sclerosis (MS), provide no additional clinical benefit when taken together. While findings published today in Annals of Neurology, a journal of the American Neurological Association and Child Neurology Society, suggest that taking both INF and GA together was not superior to GA monotherapy in reducing relapse risk; the combination therapy does appear to reduce new lesion activity and total lesion volume. The National Institute of Neurological Disorders and Stroke (NINDS) describes MS as a neuroinflammatory disease, which affects the central nervous system by attacking myelin, a substance found in nerve fibers. NINDS estimates that up to 350,000 individuals in the U.S. are diagnosed with MS, which affects twice as many women as men, with most symptoms appearing between the ages of 20 and 40. Experts believe this complex autoimmune disease may be caused by genetic and environmental factors. "While there are a number of drugs to treat MS, our study is the first to investigate if the concurrent use of two drugs with … Continue reading →

Newswise People with multiple sclerosis (MS) who were treated with combination therapy did not see significant clinical benefit over those treated with single drug therapy, but combination therapy did reduce the development of new lesions, according to an international research team led by The Mount Sinai Medical Center. The findings, part of the largest-ever MS trial sponsored by the National Institutes of Health, are published in the March 11 issue of Annals of Neurology. In the Phase III CombiRx trial, researchers led by Fred Lublin, MD, of The Mount Sinai Medical Center, sought to determine if Glatiramer Acetate (GA) and Interferon Beta-1a (IFN), the two most commonly-prescribed drugs for relapsing-remitting MS (RRMS), were more effective in combination than as monotherapies. The results showed that while combination therapy was no better than monotherapy, patients who took combination therapy had a reduction in new lesions on MRI scan. This is the first NIH-sponsored, multi-center, comparative trial evaluating the benefits of both combination therapy and monotherapy in MS, said lead author Fred Lublin, MD, Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at The Mount Sinai Medical Center. The study is the first to show that a combination trial is feasible … Continue reading →

Washington, March 11 (ANI): Hormone pulse therapy may be helpful for people whose multiple sclerosis (MS) is not well-controlled through their regular treatment, a new study has suggested. The study involved 23 people with MS who were taking beta-interferon treatment and had at least one relapse or brain scan showing new disease activity within the previous year. They were considered to have "breakthrough" MS, which means that their treatment that had been working previously stopped being effective, leading to worsening disability and more frequent relapses, as well as increased evidence of disease activity on brain scans. The study participants were given either adrenocorticotropic hormone (ACTH) or methylprednisolone as pulse therapy monthly in addition to their regular treatment for one year. The people with MS knew which treatment they were receiving, but the researchers examining them did not. The participants were tested every three months for 15 months. Over that time, those receiving ACTH had fewer relapses, or 0.08 cumulative relapses per patient compared to 0.8 relapses per patient for those receiving methylprednisolone. Those taking ACTH also had no cases of psychiatric side effects, while those taking methylprednisolone had a cumulative number of 0.55 psychiatric episodes per patient. "These results are … Continue reading →